InVivo Therapeutics, DePuy Synthes, Alphatec Spine & more: 10 device company notes

Written by Anuja Vaidya | August 11, 2017 | Print  |

Here are 10 key notes on orthopedic and spine device companies from the past week.

After temporarily halting enrollment in the INSPIRE study, InVivo announced the company is reviewing recommendations from the FDA and working toward reopening the clinical trial. The company also reported a $6.3 million net loss for the second quarter of 2017.


Alphatec reported total revenue of $24.4 million in the second quarter of 2017.


RTI Surgical reported its second quarter results with $72.1 million in revenues, a 7 percent increase.


Orthofix International saw net sales of $108.9 million in the second quarter of 2017, reflecting a 4.7 increase over the same period the year prior.


DePuy Synthes entered an exclusive agreement with Medical Enterprises Distribution.


Tissue Regenix acquired CellRight Technologies.


Bioventus named Greg Anglum its senior vice president and CFO and welcomed Anthony D'Adamio as senior vice president and general counsel.


Stimwave earned FDA clearance for its StimQ Peripheral Nerve Stimulator System.


Active Implants enrolled the 100th patient in its NUsurface Meniscus Implant clinical trials.


Patrick Noud, MD, performed the first total shoulder arthroplasty using FH Orthopedics' Arrow Prime cementless glenoid base plate.


More articles on devices:
K2M, Smith & Nephew & more: 9 device company mergers, acquisitions and agreements
RTI Surgical reports $72.1M in Q2 revenue: 5 highlights
DePuy Synthes & Medical Enterprises Distribution to co-market automated THA technology: 6 points

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months